In a quid pro quo with erstwhile partner Sanofi Pasteur, Crucell NV regained control over its cell-culture-based influenza vaccine program by agreeing not to exercise its rights, under a change-of-control clause, to terminate a contract with Sanofi Pasteur subsidiary Shantha Biotechnics Ltd. on the production of a pediatric vaccine against Haemophilus influenzae B. (BioWorld International) Read More
